119 related articles for article (PubMed ID: 17140370)
1. Molecular approaches towards characterization, monitoring and targeting of viral-associated hematological malignancies.
Yin CC; Jones D
Expert Rev Mol Diagn; 2006 Nov; 6(6):831-41. PubMed ID: 17140370
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
4. Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies.
Khanna R; Moss D; Gandhi M
Nat Clin Pract Oncol; 2005 Mar; 2(3):138-49. PubMed ID: 16264907
[TBL] [Abstract][Full Text] [Related]
5. Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.
Zhou Y; Attygalle AD; Chuang SS; Diss T; Ye H; Liu H; Hamoudi RA; Munson P; Bacon CM; Dogan A; Du MQ
Br J Haematol; 2007 Jul; 138(1):44-53. PubMed ID: 17555446
[TBL] [Abstract][Full Text] [Related]
6. Detection of specific lytic and latent transcripts can help to predict the status of Epstein-Barr virus infection in transplant recipients with high virus load.
Zawilinska B; Kosinska A; Lenart M; Kopec J; Piatkowska-Jakubas B; Skotnicki A; Kosz-Vnenchak M
Acta Biochim Pol; 2008; 55(4):693-9. PubMed ID: 19015775
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
8. A new animal model for primary and persistent Epstein-Barr virus infection: human EBV-infected rabbit characteristics determined using sequential imaging and pathological analysis.
Takashima K; Ohashi M; Kitamura Y; Ando K; Nagashima K; Sugihara H; Okuno K; Sairenji T; Hayashi K
J Med Virol; 2008 Mar; 80(3):455-66. PubMed ID: 18205213
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
10. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
11. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
14. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
15. DNA viruses in human cancer: an integrated overview on fundamental mechanisms of viral carcinogenesis.
Elgui de Oliveira D
Cancer Lett; 2007 Mar; 247(2):182-96. PubMed ID: 16814460
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of latent DNA viruses during immunosuppression: basic contemplation.
Rajcani J
Acta Virol; 2007; 51(2):77-100. PubMed ID: 17900215
[TBL] [Abstract][Full Text] [Related]
19. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation.
Engelmann I; Welte T; Fühner T; Simon AR; Mattner F; Hoy L; Schulz TF; Gottlieb J
J Clin Virol; 2009 May; 45(1):47-53. PubMed ID: 19303808
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in new and old viral infections.
Gentile G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E3. PubMed ID: 16864117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
